



SARCOPENIC OBESITY:CORRELATION WITH FUNCTIONAL LIMITATION AND QUALITY OF LIFE IN A METABOLIC-NUTRITIONAL AND PSYCHOLOGICAL REHABILITATION UNIT

Tempera S¹, Ricciardi LM¹, Guerra A¹, Savina C², Coletti C², Paolini M², Scavone L², Neri B², De Felice MR², Donini LM^{1,2}

¹ Sapienza University of Rome; Department of Experimental Medicine, Medical Physiopatology, Food Science and Endocrinology Section; Food Science and Human Nutrition Research Unit. - <u>lorenzomaria.donini@uniroma1.it</u> ² Rehabilitation Clinical Institute "Villa delle Querce" – Nemi (RM), Italy.

INTRODUCTION

Obesity/low muscle mass combination, defined as Sarcopenic Obesity (SO), due to disproportionally poor muscle strength compared to large fat mass, may lead to disability.

It may also represent an important obstacle to rehabilitation programs and to clinical outcome.

AIMS

To verify the correlation of SO with comorbidity, disability and quality of life.

MHETODS

All patients hospitalized at the Metabolic, Nutritional and Psychological Rehabilitation Unit of the "Villa delle Querce" Institute (Nemi – Rome, Italy) from January to April 2011, were considered.

Fat Mass (FM) and Fat Free Mass (FFM) (bioelectrical impedance and anthropometry), muscle strength (handgrip dynamometry - HG), physical performance (Short Physical Performance Battery – SPPB and 6-min walk test – 6MWT) and comorbidity (Charlson comorbidity index score and SIO Clinical Appropriateness Chart for the Metabolic, Nutritional and Psychological Rehabilitation of Obesity - SSA-RMN-O) were measured. Adverse clinical events (ACEs) during the rehabilitation period were considered.

The diagnosis of Obesity was made through Body Mass Index (BMI) and FM (table 1) while Sarcopenia was considered using low muscle mass index, low muscle strength and low physical performance (tables 2 and 3).

Table 1. Diagnosis of Obesity.

Table 2. Diagnosis of Sarcopenia

	Obesity		Sarcopenia
м	BMI ≥ 30 kg/m ² and FM ≥ 25%	FFM	FFM measured/ideal < 0.9
		Muscle	HG < 30 Kg M
F	BMI ≥ 30 kg/m ² and	Strenght	HG < 20 Kg F
	FM ≥ 35%	Performance	SPPB ≤ 8

 Table 3. EWGSOP conceptual stages of sarcopenia (Cruz-Jentoft AJ et al: Age Ageing. 2010)

	Muscle Mass		Muscle Strength		Performance
Pre sarcopenia	low				
Sarcopenia	low	and	low	or	low
Severe sarcopenia	low	and	low	and	low

RESULTS

At the moment 70 patients (42 women, 28 men; 59.4 ± 11 yrs) were enrolled.

The prevalence of SO is 31.4%; greater in F (40.5%) than in M (18,5%) (table 4).

Table 4. Prevalence of Sarcopenic Obesity.

	Obesity	SO	р	
F	25 (59.5%)	17 (40.5%)	0.04	
М	23 (82.1%)	5 (17.9%)		
Total	48	22		

The prevalence of SO increases with age (p = 0.036); 39.4% of subjects \ge 65 yrs old are characterized by SO, but its prevalence is important even in younger subjects (26.1%).

SO is related to greater disability (increased score to TSD-OC and decreased distance at the 6MWT).

Tendentially, in SO we found worse quality of life (SF-36), increasing comorbidity (Charlson Comorbidity index, SSA-RMN-O, drugs consumption) and ACEs (table 5).

Table 5. Correlation between	SO, functional limitation and psychological
status.	

		Obesity	SO	p
TSD-OC (%)		58.6	73.0	0.01
6MWT [distance (m) measured/expected]		0.46	0.25	0.05
	PH	31.0	24.4	0.1
SF-36	МН	32.7	27.6	0.3
	Total score	32.1	26.1	0.1
Charlson Comorbidity Index		2.6	2.6	0.9
SSA-RMN-O (pts)		39.7	42.3	0.3
ACEs (n)		0.7	1.2	0.1
Drugs (n)		6.5	8.1	0.02

CONCLUSION

SO presents a high prevalence not only in elderly subjects. Compared with "pure" obesity, SO is characterized by an increased degree of disability and comorbidity and a worse quality of life.